ClinicalTrials.gg
CompletedNCT00254514Updated Jan 23, 2017

Controlled Study to Evaluate the Efficacy and Safety of the Treatment With Growth Hormone in Tibia Fractures

A Phase 2 interventional study of somatropin in Bone Fracture and Tibia Fractures, sponsored by Novo Nordisk A/S. Completed at 40 sites in 9 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-01-23.

Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
407
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 38 studies in Fractures, Bone with a site in Germany — 6 open to participants now, 9 under way, none of them phase 3. Fractures, Bone · Germany.

Enrollment
6th of 19
407 · median 148
Started
2001
the only one that year
Phase 2
4 of 38
none open now
Registered
4th of 38
by date

Among the 38 studies in Fractures, Bone with a site in Germany, this one is the 6th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2001, is one of 4 in phase 2, and was the 4th registered.

Fractures, Bone

725 studies on the registry are indexed under Fractures, Bone; 116 are open to participants now.

Browse Fractures, Bone studies →

Open to participants now

6 of the 38 studies in Fractures, Bone with a site in Germany are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 72 Fractures, Bone studies recruiting now, 36 (50%) set no upper age limit and 22 (31%) stop at 75 or younger; 17 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Fractures, Bone with a site in Germany, or all of them as a file.
02

Study summary

This trial is conducted in Africa, Europe and Middle East. This trial investigates the efficacy and safety of three dose levels of Norditropin® (growth hormone) as compared to placebo in the treatment of tibia fractures. The trial will be conducted in two parts: in the first part, the patients will be evaluated with regard to efficacy (fracture healing) and safety at short time intervals until week 24 post-surgery. In the second part, long-term safety and fracture healing up to 12 months post-surgery will be evaluated.

03

Conditions studied

  • Bone Fracture
  • Tibia Fractures

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Primary surgical treatment of tibia fracture using intramedullary nailing
  • Closed fractures: Tscherne Type C1, C2 and C3
  • Open fractures: Gustilo Grade I, II and IIIa

Exclusion criteria

Exclusion Criteria:

  • Open growth plate on X-rays
  • Known chronic endocrine or metabolic disease including diabetes and severe obesity defined as (BMI)1 > 32.0
  • Severe head injury defined as patients who are stuporous or comatose with pupillary enlargement or asymmetry
  • Critically ill patients defined as patients in need of mechanical ventilation (except during surgical procedures) or circulatory support (defined as use of inotropic drugs)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
407 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Time from surgery until fracture has healed

    Time frame: During a 12 month period

Secondary outcomes

  1. Investigator's assessment: fracture healed

  2. Number of fractures healed

07

Study locations

40 sites
  • Novo Nordisk Investigational Site
    Kuopio, 70211, Finland
  • Novo Nordisk Investigational Site
    Oulu, 90029, Finland
  • Novo Nordisk Investigational Site
    Strasbourg, 67400, France
  • Novo Nordisk Investigational Site
    Augsburg, 86156, Germany
  • Novo Nordisk Investigational Site
    Berlin, 13353, Germany
  • Novo Nordisk Investigational Site
    Braunschweig, 38118, Germany
  • Novo Nordisk Investigational Site
    Hamburg, 20246, Germany
  • Novo Nordisk Investigational Site
    Homburg, 66421, Germany
  • Novo Nordisk Investigational Site
    Ludwigshafen, 67071, Germany
  • Novo Nordisk Investigational Site
    Mainz, 55131, Germany
  • Novo Nordisk Investigational Site
    München, 81366, Germany
  • Novo Nordisk Investigational Site
    Münster, 48149, Germany
  • Novo Nordisk Investigational Site
    Offenbach, 63069, Germany
  • Novo Nordisk Investigational Site
    Würzburg, D-97080, Germany
  • Novo Nordisk Investigational Site
    Budapest, 1076, Hungary
  • Novo Nordisk Investigational Site
    Budapest, H-1043, Hungary
  • Novo Nordisk Investigational Site
    Budapest, H-1081, Hungary
  • Novo Nordisk Investigational Site
    Budapest, H-1125, Hungary
  • Novo Nordisk Investigational Site
    Gyor, 9024, Hungary
  • Novo Nordisk Investigational Site
    Miskolc, H-3526, Hungary
  • Novo Nordisk Investigational Site
    Veszprém, H-8200, Hungary
  • Novo Nordisk Investigational Site
    Beer Sheva, 84101, Israel
  • Novo Nordisk Investigational Site
    Haifa, 31096, Israel
  • Novo Nordisk Investigational Site
    Jerusalem, 91120, Israel
  • Novo Nordisk Investigational Site
    Kfar Save, 44281, Israel
  • Novo Nordisk Investigational Site
    Tel-Aviv, 64239, Israel
  • Novo Nordisk Investigational Site
    Lillestrøm, 2004, Norway
  • Novo Nordisk Investigational Site
    Oslo, 0407, Norway
  • Novo Nordisk Investigational Site
    Gorzów, 66-400, Poland
  • Novo Nordisk Investigational Site
    Krakow, 31-826, Poland
  • Novo Nordisk Investigational Site
    Piekary Slaskie, 41-940, Poland
  • Novo Nordisk Investigational Site
    Sosnowiec, 41-200, Poland
  • Novo Nordisk Investigational Site
    Szczecin-Zdunowo, 70-890, Poland
  • Novo Nordisk Investigational Site
    Durban, KwaZulu-Natal 4001, South Africa
  • Novo Nordisk Investigational Site
    Cape Town, Western Cape 7505, South Africa
  • Novo Nordisk Investigational Site
    Cape Town, Western Cape 7925, South Africa
  • Novo Nordisk Investigational Site
    Cape Town, Western Cape, South Africa
  • Novo Nordisk Investigational Site
    Worcester, 6850, South Africa
  • Novo Nordisk Investigational Site
    Madrid, 28041, Spain
  • Novo Nordisk Investigational Site
    Valencia, 46026, Spain
08

References and documents

Publications

  • Raschke M, Rasmussen MH, Govender S, Segal D, Suntum M, Christiansen JS. Effects of growth hormone in patients with tibial fracture: a randomised, double-blind, placebo-controlled clinical trial. Eur J Endocrinol. 2007 Mar;156(3):341-51. doi: 10.1530/EJE-06-0598. PubMed 17322494 ↗
  • Krusenstjerna-Hafstrom T, Rasmussen MH, Raschke M, Govender S, Madsen J, Christiansen JS. Biochemical markers of bone turnover in tibia fracture patients randomly assigned to growth hormone (GH) or placebo injections: Implications for detection of GH abuse. Growth Horm IGF Res. 2011 Dec;21(6):331-5. doi: 10.1016/j.ghir.2011.08.003. Epub 2011 Oct 1. PubMed 21963127 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2001, a primary completion of Oct 2003 and a completion of Oct 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2005
First posted
Nov 16, 2005
Start
Aug 2001
Primary completionActual
Oct 2003
CompletionActual
Oct 2003
Last update
Jan 23, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00254514
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Nov 16, 2005
Start date
Aug 2001
Primary completion
Oct 2003
Completion
Oct 2003
Last update
Jan 23, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion